BFS
IMMU

Bradley Foster & Sargent’s Immunomedics Inc IMMU Stock Holding History

Bradley Foster & Sargent’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,000
Closed -$200K – 353
2018
Q4 		$200K Sell
14,000
-250
-2% -$4.96K 0.01% 332
2018
Q3 		$297K Buy
+14,250
New +$338K 0.01% 323

Other funds holding IMMU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bradley Foster & Sargent's IMMU Position: Q1 2019 in Review

Bradley Foster & Sargent sold out of Immunomedics Inc (IMMU) in Q1 2019, closing a stake of 14,000 shares — an estimated $200K sold.

Bradley Foster & Sargent first reported a position in IMMU in Q3 2018 and held it in 2 quarters. The position peaked at $297K in Q3 2018. 204 funds tracked by Wall St. Rank hold IMMU as of Q1 2019.

  • Bradley Foster & Sargent reported no remaining Immunomedics Inc position as of Q1 2019 after selling out during the quarter.
  • Bradley Foster & Sargent sold 14,000 Immunomedics Inc shares in Q1 2019, an estimated $200K.
  • Bradley Foster & Sargent first reported a position in Immunomedics Inc in Q3 2018 and held it in 2 quarters.
  • Bradley Foster & Sargent's Immunomedics Inc position peaked at $297K in Q3 2018.
  • 204 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2019.

Based on Bradley Foster & Sargent's 13F filing for Q1 2019, filed 2 May 2019.